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Abstract
Diabetes and metabolic syndrome are associated with abnormal postprandial lipoprotein metabolism, with a significant delay in the
clearance of many lipid parameters, including triglycerides and chylomicrons. Abnormal concentrations of plasma lipids can result from
changes in the production, conversion, or catabolism of lipoprotein particles. Whereas the liver is involved in controlling serum lipid levels
through synthesis of liver derived triglyceride-rich lipoproteins and low-density lipoprotein metabolism, the intestine also has a major role
in lipoprotein production. Postprandial lipemia results from increases in apoB-48 availability, lipogenesis, and the synthesis and absorption
of cholesterol in the enterocytes. Increased intestinal lipoprotein production prolongs postprandial lipemia in patients with diabetes and
MetS, and may contribute directly to atherogenesis in these patients.
© 2015 Elsevier Ireland Ltd. All rights reserved.
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1. Abnormalities of lipoprotein metabolism in diabetes
mellitus and metabolic syndrome
Dyslipidemia associated with diabetes mellitus and
metabolic syndrome (MetS) is characterized by a clus-
ter of metabolically interrelated lipoprotein abnormalities.
Due to the elevated atherogenic potential of these abnor-
malities they are usually comprehensively designated as
atherogenic dyslipidemia (AD). The phenotypic hallmarks
of AD are increased plasma triglycerides (TG), reduced
high-density lipoprotein cholesterol (HDL-C) and increased
numbers of small, dense low-density lipoprotein (sdLDL)
particles.
Abnormal concentrations of plasma lipids can result
from changes in the production, conversion, or catabolism
of lipoprotein particles. Therefore, several studies have
investigated the kinetic parameters of apoB-containing
lipoproteins [low-density lipoprotein (LDL) and very-low-
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density lipoprotein (VLDL)] to identify the mechanisms
responsible for AD. These studies have consistently re-
ported that the major metabolic defects in AD are increased
VLDL production, and reduced catabolism of LDL and its
precursor, intermediate-density lipoprotein (IDL).
Overproduction of VLDL is particularly evident in
patients with diabetes, where this abnormality is related
to the plasma glucose level and indices of tissue insulin
sensitivity such as the HOMA index. In addition, intra-
abdominal and liver fat are also significant predictors of
liver production of large TG-rich VLDL [1].
Assessment of HDL metabolism in subjects with dia-
betes using a stable isotope method revealed a higher than
normal mean fractional catabolic rate (FCR) of apoAI-
HDL, strongly suggesting that HDL is catabolized more
rapidly in these patients. Therefore, the AD phenotype can
result from: 1) increased production of VLDL, 2) a reduced
catabolic rate of apoB-containing lipoproteins (IDL and
LDL), and 3) an increased catabolic rate of HDL.
The liver plays a fundamental role in cholesterol home-
ostasis, because it processes cholesterol taken up from
plasma lipoproteins and chylomicrons, and uses cholesterol
to form bile acids that are subsequently secreted into the
bile. As the major site of LDL catabolism, the liver also
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has a part in determining plasma LDL levels. As described
elsewhere in this supplement [2], the liver is not the only
organ with an important role in this process: also the intes-
tine plays an essential role. In diabetes mellitus or MetS,
chylomicrons produced in the intestine can accumulate in
the circulation thereby influencing overall lipid and lipopro-
tein turnover. There are indications that chylomicrons and
cholesterol metabolism in the intestine are involved in
regulating plasma LDL concentrations [3].
2. Abnormalities in intestinal lipids and lipoprotein
metabolism in diabetes and metabolic syndrome
Patients with diabetes have abnormal post absorptive
lipoprotein metabolism, with a significant delay in the
postprandial clearance of many lipid parameters, including
triglycerides and chylomicrons, in spite of normal fasting
levels [4]. Similar results have been observed in people with
MetS [5]. This is observed even if subjects are categorized
according to insulin resistance.
Chylomicrons are lipoprotein particles secreted by the
intestine during the postprandial period. Their assembly
is a complex, multistep process (Fig. 1), in which apoB-
48 synthesis is one of the limiting factors [6]. Duez
et al. hypothesized that abnormalities in the synthesis
of intestinally-derived apolipoproteins drive the prolonged
postprandial phase in insulin-resistant subjects, and ex-
amined the relationship between insulin resistance and
the rate of production of intestinal lipoproteins [7]. They
found that ApoB-48 was produced at a significantly higher
rate in hyperinsulinemic, insulin-resistant subjects and that
this correlated with fasting plasma insulin concentrations.
Consistent with this observation, others have reported that
insulin administration decreases levels of circulating apoB-
48-containing lipoproteins [8].
Fig. 1. Regulation of chylomicron synthesis. ApoB-48, apoproptein B-48; ABCG, ATP-binding cassette sub-family G member; ACAT, Acyl-
CoA:cholesterol acyltransferase; HMGCoA, hydroxy-3-methyl-glutaryl-CoA. (Reproduced with permission from Diabetes Care 2008; 31(Suppl. 2):
S241–8.)
More recent evidence indicates that the adipokine resistin
is also involved in regulating chylomicron assembly. Plasma
resistin concentrations are elevated in MetS and associated
with insulin resistance [9]. In cultured hepatocytes, resistin
stimulates the overproduction of VLDL apo-B by increasing
the activity of the microsomal transfer protein (MTP),
which plays a pivotal role in coupling triglycerides with
apoB-48 in chylomicrons (Fig. 1), and by decreasing insulin
signaling [10].
Chylomicron assembly is also influenced by the avail-
ability of cholesterol in enterocytes. Regulation of chy-
lomicron cholesterol is depicted in Fig. 2. Cholesterol is
absorbed through a process facilitated by the Niemann-
Pick C1-Like 1 (NPC1L1) protein, which plays the major
quantitative role in intestinal cholesterol absorption. In ad-
dition, ABCG5 and ABCG8 proteins regulate enterocyte
cholesterol content by promoting its re-excretion into the
intestinal lumen throughout the intestinal villi.
NPC1L1 mRNA expression is elevated in patients with
type 2 diabetes [11], suggesting that cholesterol absorption
is increased. Moreover, these patients also have increased
expression of MTP, associated with reduced expression of
the cholesterol efflux transporters ABCG5 and ABCG8
(Fig. 3). Taken together, this pattern strongly support the
notion that diabetic patients have elevated amounts of
enterocyte cholesterol available for chylomicron assembly.
Based on these observations, one could hypothesize that
the modulation of intestinal cholesterol metabolism might
be a useful strategy for controlling the exaggerated post-
prandial lipemia in insulin-resistant conditions (diabetes
mellitus and MetS). Ezetimibe is a compound that specifi-
cally reduces intestinal cholesterol absorption by inhibiting
the activity of NPC1L1 [12]. Administration of ezetimibe
to men with moderate primary hypercholesterolemia in-
creases the fractional catabolic rate of apoB-100-containing
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Fig. 2. Chylomicron cholesterol derives from dietary, biliary and intestinal de novo synthesized cholesterol. NPC1-L1 regulates its absorption and
ABCG5 and ABCG8 regulate its excretion. MTP assembles the apoB-48 protein, cholesterol and other lipids to form the chylomicron, which is then
secreted into the lymph. (Reproduced with permission from Diabetes Care 2008 Feb;31 Suppl 2:S241–8 [6].)
Fig. 3. Comparison of mRNA expression of intestinal proteins regu-
lating cholesterol absorption and chylomicron composition in diabetic
(n= 15) (black bars) and non-diabetic control patients (n= 17) (white
bars) not receiving statin treatment. a) microsomal triglyceride transfer
protein (MTP) and Niemann-Pick C1-like 1 (NPC1-L1); b) ATP-binding
cassette, transporters G5 and G8 (ABCG5/G8). Mean ± SE, *p< 0.05,
**p< 0.02 compared to control subjects. (Reproduced with permission
from Diabetologia 2006 May;49(5):1008–16 [11].)
lipoproteins, with an associated decrease in this lipoprotein
fraction [13], which is considered the major mechanism of
action of this drug. However, several studies have demon-
strated that ezetimibe has a beneficial effect also on post-
prandial triglyceride-rich lipoproteins in patients with type
2 diabetes. For example, postprandial chylomicron apoB-48
concentrations were about 50% lower in subjects with type
2 diabetes and hypercholesterolemia receiving simvastatin
+ ezetimibe, compared with simvastatin + placebo (Fig. 4)
[14]. This decrease suggests that ezetimibe reduces the
number of intestinal particles, confirming the results from
the kinetic study in men with mixed hyperlipidemia cited
above [13].
Chylomicron cholesterol content was also significantly
lower after ezetimibe compared to placebo, even in the
fasting state, and this difference remained statistically sig-
nificant during the entire postprandial phase. Postprandial
levels of chylomicron triglycerides and the cholesterol/
triglyceride ratio were also significantly lower with ezetim-
ibe, compared to placebo, as were the levels of apoB.
3. Contribution of insulin resistance-related
perturbation of intestinal lipid metabolism to
cardiovascular risk in patients with diabetes or
metabolic syndrome
During the postprandial phase, triglyceride-rich lipopro-
teins (chylomicrons and VLDL) are converted into partially
hydrolyzed lipoproteins known as remnant-like particles
(RLPs) which represent transient lipoprotein particles rel-
atively enriched in apoB and cholesterol. Therefore, exag-
gerated postprandial lipemia may favor the production of
elevated amounts of RLPs. Several epidemiological stud-
ies have indicated that RPLs significantly contribute to
atherogenesis. The Honolulu Heart Study [15], a 17-year
prospective study that followed a cohort of 1156 Japanese-
American men aged 60 to 82, documented 164 incident
cases of CHD, and found that elevated RLPs levels were as-
sociated with a 2-fold increase in CHD risk after adjustment
for potential confounding variables.
Finally, there are direct demonstrations that RLPs can
be retained in arterial vessels, and that this phenomenon
is modulated by insulin sensitivity. Mangat et al. investi-
gated arterial retention of intestinal-derived remnants using
labeled RLPs in an ex vivo system in the JCR:LA-cp
rat model of insulin resistance, in order to identify po-
tential mechanisms of exacerbated cholesterol deposition
in insulin resistance [16]. They found significantly more
retention in hyperinsulinemic animals, suggesting that the
insulin resistant state adversely affect the interaction of
lipoprotein metabolism with the arterial wall. However,
arterial RLP retention was significantly reduced when
hyperinsulinemic animals were treated with ezetimibe or
ezetimibe+simvastatin. These observation indicate that the
arterial retention of cholesterol-rich remnants may explain
part of the association between insulin resistant states (dia-
betes mellitus and MetS) and atherosclerosis, and suggests
that ezetimibe alone or in combination with a statin could
reduce the risk of atherosclerotic vascular damage under
these conditions.
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Fig. 4. Postprandial cholesterol, triglycerides, cholesterol/triglyceride ratio, and apoB-48 concentrations in chylomicrons with ezetimibe and placebo
treatment in patients with type 2 diabetes. *p< 0.05 by paired samples t-test. (Reproduced with permission from Atherosclerosis. 2011 Jul;217(1):142–8
[14].)
4. Conclusions
Atherogenic dyslipidemia is very common in insulin
resistant conditions such as diabetes and MetS. In addition
to increased hepatic synthesis of liver derived triglyceride-
rich lipoproteins (VLDL), these conditions are associated
with increased intestinal lipoprotein production. This results
from increases in apoB-48 availability, lipogenesis, and the
synthesis and absorption of cholesterol in the enterocytes.
Increased intestinal lipoprotein production prolongs post-
prandial lipemia in patients with diabetes and MetS, and
may contribute directly to atherogenesis in these patients.
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